Contact Us

News Room

EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference

5-17-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

5-16-22

EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments

5-4-22

EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan

5-4-22

EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

4-27-22

EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference

4-21-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

4-18-22

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

3-16-22

EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley Bank

3-9-22

EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer

3-7-22

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments

3-3-22

EyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care Conference

3-1-22

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

2-24-22

EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

2-12-22

EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements

1-10-22

EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

1-10-22

Load More

EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EyePoint and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc. With an Eye on Patients is a trademark of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EyePoint, the EyePoint logo, and Delivering Innovation to the Eye are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EyePoint, the EyePoint logo, YUTIQ, Durasert, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc. Verisome is a registered trademark of Ramscor, Inc. All other trademarks are the property of their respective owners.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EyePoint, the EyePoint logo, YUTIQ, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EyePoint, the EyePoint logo, the YUTIQ logo, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EyePoint, the EyePoint logo, YUTIQ, the YUTIQ logo, and Durasert are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EyePoint, the EyePoint logo, DEXYCU, and the DEXYCU logo are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EyePoint, the EyePoint logo, Durasert, YUTIQ, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

EyePoint, the EyePoint logo, YUTIQ, and DEXYCU are registered trademarks of EyePoint Pharmaceuticals, Inc.
©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

04/2021
US-EYP-2100003

Linkedin Facebook Twitter